+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Irinotecan"

Small Cell Lung Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Small Cell Lung Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 100 Pages
  • Global
From
From
From
From
From
From
From
Colon Cancer Treatment Drugs Markets in China - Product Thumbnail Image

Colon Cancer Treatment Drugs Markets in China

  • Report
  • July 2023
  • 199 Pages
  • China
From
From
  • 12 Results (Page 1 of 1)
Loading Indicator

Irinotecan is a semi-synthetic derivative of the natural product camptothecin, a quinoline alkaloid found in the bark of the Chinese tree Camptotheca acuminata. It is used as an antineoplastic agent in the treatment of a variety of cancers, including colorectal, lung, ovarian, and pancreatic cancer. Irinotecan is a topoisomerase I inhibitor, meaning it interferes with the enzyme topoisomerase I, which is involved in DNA replication. Irinotecan is available in both generic and branded forms, with the branded form being marketed under the trade name Camptosar. It is available in both intravenous and oral formulations, and is typically administered in combination with other chemotherapy agents. The Irinotecan market is highly competitive, with a number of major players operating in the space. These include Pfizer, Teva Pharmaceuticals, Mylan, Sandoz, and Sun Pharmaceuticals. Additionally, there are a number of smaller players operating in the market, such as Dr. Reddy's Laboratories, Intas Pharmaceuticals, and Natco Pharma. Show Less Read more